Moderna Reports $1 Billion Revenue in Q3 2025 Amidst Narrowed 2025 Financial Projections

Moderna, Inc. reported a third-quarter revenue of $1 billion for 2025, marking a 45% decrease compared to $1.9 billion in the same period from 2024. The company also reported a GAAP net loss of $200 million, translating to a loss per share of $0.51. Despite these declines, Moderna has adjusted its 2025 projected revenue range to $1.6 - $2.0 billion and improved its expected GAAP operating expenses.

COVID-19 vaccine sales in the third quarter contributed $971 million, with approvals received in 40 countries and successful launches of mNEXSPIKE in the US. Moderna has also advanced its RSV vaccine, mRESVIA, reporting modest sales of $2 million. Cost-reduction efforts have seen operating expenses lowered and a projected year-end cash balance expected to range from $6.5 billion to $7 billion, up from previous estimates.

CEO Stéphane Bancel emphasized operational excellence and financial discipline. Upcoming updates are anticipated for their business and pipeline on November 20 at their Analyst Day.